Sutro Biopharma, Inc.: Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating

Related Keywords

Chicago ,Illinois ,United States ,Hebron ,Israel General ,Israel ,Canada ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,American ,Sutro Biopharma ,Anne Borgman ,Luveltamab Tazevibulin ,Bristol Myers Squibb ,Amy Bonanno ,Astellas Pharma ,Anniej Chang ,American Society Of Clinical Oncology ,Exchange Commission ,Hebron University Hospital ,Solebury Strategic Communications ,Sutro Biopharma Inc ,Hebron Institute Of Oncology ,Clinical Oncology ,Annual Meeting ,Principal Investigator ,Ana Oaknin ,Gynecological Tumor Unit ,Attending Physician ,Principal Clinical Investigator ,Gynecological Malignancies Group ,Hebron Institute ,Tumor Proportion Score ,Chief Medical ,South San Francisco ,Private Securities Litigation Reform Act ,Fast Track ,Sutro ,Iopharma ,Nnounces ,Mural ,Presentation ,Disco ,023 ,Eaturing ,Data ,Uveltamab ,Azevibulin ,Rom ,Hase ,Nose ,Expansion ,Study ,Ovarian ,Dancer ,Initiation ,Pivotal ,Ireframe ,